These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 19933960)
1. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
2. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data". Luepker RV Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016 [No Abstract] [Full Text] [Related]
3. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
4. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
5. Vioxx's history and the need for better procedures and better testing. Gilhooley M Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218 [No Abstract] [Full Text] [Related]
6. The Vioxx fallout. Palmer K Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592 [No Abstract] [Full Text] [Related]
10. Don't blame it all on the bogey. Day M BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929 [TBL] [Abstract][Full Text] [Related]
11. Drug safety special: the safety catch. Wadman M Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591 [No Abstract] [Full Text] [Related]
12. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Ross JS; Madigan D; Hill KP; Egilman DS; Wang Y; Krumholz HM Arch Intern Med; 2009 Nov; 169(21):1976-85. PubMed ID: 19933959 [TBL] [Abstract][Full Text] [Related]
13. Withdrawal of rofecoxib - a wake up call for drug safety. Mishra P; Palaian S Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250 [No Abstract] [Full Text] [Related]
14. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
15. International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. Metcalfe C; Wheeler BW; Gunnell D; Martin RM Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):778-85. PubMed ID: 20680998 [TBL] [Abstract][Full Text] [Related]
16. The vexations of Vioxx. Sibbald B CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046 [No Abstract] [Full Text] [Related]
17. Drug safety on trial. Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579 [No Abstract] [Full Text] [Related]